1. August 02, 2007
Molecular Design of
Histone Deacetylase Inhibitors with
Aromatic Ring Arrangement
Gururaj Mahadev Shivashimpi
Student Number: 04897021-1
Graduate School of Life Science and Systems Engineering
Kyushu Institute of Technology, Kitakyushu, Japan
2. Basis of the present work
HDAC8
A family of enzymes known as histone deacetylases (HDACs) helps to regulate
how and when our genome blueprint is transcribed and translated into protein.
HDAC enzymes have proven to be exciting and promising novel targets for the
treatment of solid tumors and hematological cancers.
Inhibitors of these enzymes are proposed to function through their ability to modify
the acetylation of histone tails, modifying the expression of oncogenes and tumor
suppressor genes, and rescuing normal cell growth and differentiation.
Small-molecule inhibitors of these enzymes are thus under intense investigation
as cancer therapeutics, as evidenced by extensive research in this field.
Kyushu Institute of Technology
3. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
4. Introduction
Schematic structure of nucleosome
Major post translational
modifications
A Acetylation
M Methylation
Ub Ubiquitination
P Phosphorylation
Mai, A., Massa, S., et al. Med. Res. Rev. 2005, 25, 261–309.
The nucleosome, the fundamental unit of chromatin, consists of a histone octamer wrapped
with 146 base pairs of DNA . The histone octamer composed each of the four core histones
H2A, H2B,H3 and H4. The basic N-terminal histone tails protrude from the core nucleosome.
Kyushu Institute of Technology
5. Histone tail acetylation and bromodomain
de la Cruz, X., et al. Bioessays 2005, 27, 164-175.
Kyushu Institute of Technology
6. Structure and functions of bromodomain
• It adopts typical left handed four helix bundle shape
(NMR studies).
• Interaction Ac-Lys occurs at hydrophobic pocket
• It plays important role in
- chromatin acetylation through HAT recruitment
- organizing chromatin domains
- recognizing acetylated non-histone proteins
Figure. Structure of bromodomain
Dhalluin, C., et al. Nature 1999, 399, 491-496.
Kyushu Institute of Technology
7. Histone deacetylases
HDAC enzymes deacetylate the ε-amino groups of lysine residues in the N-terminal tails
of core histones leading to a compacted chromatin structure due to strong interaction of ε-
amino lysine residues with DNA.
- Gene transcription repressed by altering the accessibility of transcription
factors to DNA.
- Inappropriate recruitment of HDAC enzymes by oncogenic proteins may
alter gene expression in favor of arrested differentiation, and/or excessive proliferation.
- Inhibition of these HDACs leads to the accumulation of acetylated histones to
activate transcription causing inhibition of tumor cell growth and induction of apoptosis.
Kyushu Institute of Technology
8. HDAC isoforms
Zn+2 ion
dependent
enzymes
NAD
dependent Sir2
family
Kyushu Institute of Technology
9. Historical opening: Structure of A. aeolicius HDLP active site
bound to trichostatin A
Finnin, M. S., Donigian, J. R., et al. Nature 1999, 401, 188-193.
Kyushu Institute of Technology
10. Proposed catalytic mechanism for the deacetylation of Ac-Lys
Finnin, M. S., Donigian, J. R., et al. Nature 1999, 401, 188-193.
Kyushu Institute of Technology
11. Non-peptide HDAC inhibitors with different zinc ligands
Naturally occurring inhibitors Synthetic inhibitors
Miller, T. A., et al. J. Med. Chem. 2003, 46, 5097-5116.
Kyushu Institute of Technology
12. Naturally occurring cyclic tetrapeptide inhibitors
Containing epoxy ketone moiety Containing ketone moiety
Trapoxin A (n = 2), Trapoxin B (n = 1) FR235222
Tan-1746
Chlamydocin
Apicidin
Cyl 1 (n= 1), Cyl 2 (n= 2)
Kyushu Institute of Technology
13. How to design an HDAC inhibitor?
Three major features
- terminal group to bind the zinc in the
active site of enzymes
- linker unit, residing in the channel
- capping group that principally occupies
the external entrance to the channel of
the enzyme
Structure of histone deacetylase-like
protein (HDLP) co-crystallized with TSA *
*Finnin, M. S., Donigian, J. R., et al.
Nature 1999, 401, 188-193.
Kyushu Institute of Technology
14. Cyclic tetrapeptide based synthetic HDAC inhibitors
Cancer Res. 2001, 61, 4459-4466. Bioorg. Med. Chem. Lett. 2004, 14, 2427-2431.
Org. Lett. 2003, 05, 5079-5082. Bioorg. Med. Chem. Lett. 2004, 14, 5343-5346.
Kyushu Institute of Technology
15. Purpose of present study
X-ray crystal study reveals,
favorable interaction of cap group of inhibitor and HDAC enzyme
may afford better binding affinity
Molecular design of inhibitor by arranging aromatic rings in cap group
Kyushu Institute of Technology
16. • Introduction
• Molecular design of histone deacetylase inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
17. Chlamydocin scaffold
Cyclic imino
acid site
O Spacing chain
O N HN X
NHHN
NHHN O Zn2+ ligand
toward reactive site
Aromatic group
site O
Aib site
Kyushu Institute of Technology
18. Aromatic ring replacement in chlamydocin framework
(Work carried out by Dr. Preeti and Ms. Li)
L-Ala
L-Leu
Design of cyclic tetrapeptides
cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)
L-Ile
cyclo(-L-Am7(S2Py)-Aib-L-Leu-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ile-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Nle-D-Pro-)
L-Nle
Kyushu Institute of Technology
19. Assay methods
HDAC Inhibitory Activity (Cell free assay) Excitation = 380 nm,
Emission = 460 nm
Enzyme/buffer 18 µL
Inhibitor/DMSO 1 µL Trypsin/buffer 30 µL
Substrate/DMSO 1 µL
30 min., 370C 15 min., 370C
Substrate: KGLGK-MCA KGLGK and AMC
KGLGK(Ac)-MCA KGLGK(Ac)-MCA KGLGK(Ac)-MCA
Fluorescence intensity of AMC was
measured for the HDAC activity
IC50 = Concentration of 50% inhibition
Enzyme: HDAC1
(100% = no enzyme)
1 x 107 293T cell i) Homogenize ii) Centrifuge
iii) Agarose beads, 4 0C, 1 h.
HDAC1
pcDNA-3-HD1 1 mg
Buffer (modified lysis buffer)
Lipofect Amine 2000 reagent iv) Wash agarose beads
50 mM Tris·HCl (pH 7.5)
120 mM NaCl
p21 Promoter Assay (Cell based assay) 5 mM EDTA
0.5% Nonidet P-40
MFLL-9 cell 85000 unit/well
Inhibitor/DMSO 10 mM
6h 18 h
Merged gene of wild human p21 Luminescent intensity was
promoter and luciferase measured for the luciferace activity
Kyushu Institute of Technology
20. Enzyme inhibition and biological activity
(With 0.1 mM DTT)
.
*column: Chromolith performance RP-18e (100 x 4.6 mm)
eluent: 10-100% CH3CN gradient containing 0.1% TFA over 15 min.
• Replacing of aromatic ring of L-Phe in chlamydocin showed 10 fold less activity in p21
promoter assay.
• Aromatic ring is necessary in cyclic cap group for better binding with surface of HDAC enzyme.
• By these results, further investigations were carried out by focusing on aromatic ring in the
chlamydocin framework.
Kyushu Institute of Technology
22. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
23. Aromatic ring shifting in chlamydocin framework
Design of cyclic tetrapeptides
cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
A2in A1in 2MePhe Tic
Kyushu Institute of Technology
24. • Shifting the aromatic ring of L-Phe in chlamydocin may give different orientations for
aromatic ring.
• To know proper orientation of aromatic ring showing better binding affinity in inhibition
of HDAC enzymes.
Cyclic framework Possible orientations of benzene ring
on cyclic framework
His
+2 Asp
S- Zn
Asp
Surface of HDAC enzyme
Kyushu Institute of Technology
25. Synthesis of cyclic tetrapeptides
L-Ab7* AA L-Ala D-Pro/D-Tic
Z OH H OtBu
DCC, HOBt
Z OtBu
H2, Pd-C
Pd-
Z OH H OtBu
DCC, HOBt
Z OtBu
H2, Pd-C
Pd-
Boc OH H OtBu
DCC, HOBt
Boc OtBu
TFA
TFA・
TFA・H OH
HATU, DIEA
cyclo(
cyclo( )
*L-Ab7: L-2-amino-7-bromo heptanoic acid.
AA: A2in, DL-A1in, DL-2MePhe
Kyushu Institute of Technology
26. Scheme 1. Reagents and conditions: (a) AcSK, DMF, r. t.; (b) 2,2’-dipyridyl disulphide, MeNH2/MeOH
cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
Kyushu Institute of Technology
27. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
28. Variation of spacer length of L-Phe in chlamydocin framework
n = 0, 2, 3
Design of cyclic tetrapeptides
cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
Phg Ph4 Ph5 Ser(Bzl) Ser
Kyushu Institute of Technology
29. Variation of spacer of L-Phe in chlamydocin may show
better binding Affinity in inhibition of HDAC enzymes.
Cyclic framework
( )n
S- O
Zn2
+
+
+
+ His
Asp
Asp
Surface of HDAC enzyme HO
Kyushu Institute of Technology
30. Synthesis of cyclic tetrapeptides
L-Ab7* Aib AA D-Pro
Z OH H OtBu
DCC, HOBt
Z OtBu
H2, Pd-C
Pd-
Z OH H OtBu
DCC, HOBt
Z OtBu
H2, Pd-C
Pd-
Boc OH H OtBu
DCC, HOBt
Boc OtBu
TFA
TFA・
TFA・H OH
HATU, DIEA
cyclo(
cyclo( )
*L-Ab7: L-2-amino-7-bromo heptanoic acid.
AA: L-Phg, L-Ph4, L-Ph5, L-Ser(Bzl) and L-Ser
Kyushu Institute of Technology
31. Scheme 1. Reagents and conditions: (a) AcSK, DMF, r.t.; (b) 2,2’-dipyridyl disulphide, MeNH2/MeOH
cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
Kyushu Institute of Technology
32. Enzyme inhibition and biological activity
(With 0.1 m M DTT)
*column: Chromolith performance RP-18e (100 x 4.6 mm). Eluent: 10-100% CH3CN gradient containing 0.1% TFA over 15 min.
† Selectivity among HDAC1 and HDAC4
Kyushu Institute of Technology
33. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
34. Enzyme inhibition and biological activity of diastereomers
(With 0.1 mM DTT)
IC50 (µM) p21 promoter assay.
No. Compounds
HDAC1 HDAC4 HDAC6 EC1000 (µM)
4 cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) 0.0027 0.0024 0.0120 0.055
5 cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) 0.0360 0.0250 0.0329 2.0
6 cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) 0.1700 0.0700 0.0710 25.6
7 cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) 0.0037 0.0022 0.0560 0.55
1. Conformational analysis of diastereomers by CD spectra
2. cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)
4. cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
5. cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
6. cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
7. cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
• At 220 nm region, compounds 4 and 7 show
-ve ellipticity, but 5 and 6 show +ve ellipticity.
• Compounds with –ve ellipticity show good
biological activity.
Kyushu Institute of Technology
35. 2. Conformational analysis of diastereomers by NMR spectrometry
Compound 4 Compound 5
Kyushu Institute of Technology
36. Molecular architecture of HDAC1 and HDAC8 with compound 4
(Study carried out by Dr. Y. Hirashima )
HDAC1 & Comp. 4
• Compound 4 binds in the active site of
HDAC1 and HDAC8.
• The thiol group, attached with its long
aliphatic chain lying in the 11 Å channel,
binds to the Zn+2ion at the bottom of this
channel.
• In HDAC1, the aromatic ring of D-A1in is bent
toward Glu98, Asp99, and Pro29 residues
• In HDAC8 the aromatic ring if D-A1in is bent
Human HDAC8 & Comp.4 toward Pro273 and Tyr306
Kyushu Institute of Technology
37. Summary
• We have synthesized a library of novel chlamydocin analogs by shifting the
aromatic ring of L-Phe and also varying its spacer length
• The cell-free and cell-based HDAC inhibitory activity of the inhibitors was
evaluated and it was found that most of the inhibitors are potent toward HDACs.
• The cyclic tetrapeptides 4 and 12 containing D-A1in and L-Ser(Bzl) were found
potent inhibitors among synthesized compounds..
• Conformational changes were observed in diastereomers 4/5 and 6/7 due to
aromatic ring shifting.
• Docking of compound 4 with D-A1in into HDAC1 and HDAC8 revealed the
interaction of aromatic ring in cap group with hydrophobic residues on surface of
HDAC enzymes.
Kyushu Institute of Technology
38. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
39. Non-peptide HDAC inhibitors
1. Non-peptide HDAC inhibitors with aromatic cap group:
Trichostatin A SAHA
Oxamflatin
2. Non-peptide HDAC inhibitors without aromatic cap group:
Depudecin Butyric acid Valproic acid
(Miller, T. A., et al. J. Med. Chem. 2003, 46, 5097-5116)
• Most of non-peptides containing aromatic cap group are found to be potent inhibitors
of HDACs, than those inhibitors which do not have aromatic cap group.
• Aromatic cap group is needed to interact with surface of HDAC enzymes for better
inhibition.
Kyushu Institute of Technology
40. Recently reported potent non-peptide HDAC inhibitors
(Potent non-peptide HDAC inhibitors containing bulkier aromatic cap groups)
(Shinji, C., et al. Bioorg. Med. Chem. 2006, 14, 7625-7651)
(Marson, C., et al. Bioorg. Med. Chem. Lett.
2006, 17, 136-141) (Marson, C., et al. J. Med. Chem. 2006, 49, 800-805)
Kyushu Institute of Technology
41. Design of non-peptide inhibitors with aromatic cap group in the light
of cyclic tetrapeptide thioethers
O
• Chlamydocin thioether analogues have cyclic
O N HN R
S tetrapeptide cap group.
NH HN O • These compounds were found potent in inhibiting
O HDACs.
Hirashima, Y., et al. • But, synthesis of cyclic tetrapeptides is laborious
Proceedings of 29tth European Peptide Symposium
and expensive process.
(J. Pep. Sci.) 2007 (in press).
1. SAHA analogues 2. TSA like non-peptides
O O
O
H OH
N OH N
N H
H N
O
H O
N S
R S
R
O n= 1, 2
R1
O
R = -CH2COCF3, -CH2COCH3, -CH2-4-C5H4N, -CH2C6H5, -CH2COC6H5, and -S-2-C5H4N
R1 = -H, or –CONHCH3
Kyushu Institute of Technology
42. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusion
• References
43. Synthesis of SAHA analogues
Scheme 1. Reagents and conditions: (a) AcSK, DMF, r.t.; (b) MeNH2/MeOH, R-Br, Et3N
Scheme 2. Reagents and conditions: (a) o-amino thiophenol, Et3N, DMF, r.t.
Scheme 3. Reagents and conditions: (a) 2,2’-dipyridyl disulphide, MeNH2/MeOH, DMF, r.t.
Kyushu Institute of Technology
44. Enzyme inhibition and biological activity
*column: Chromolith performance RP-18e (100 x 4.6 mm)
eluent: 10-100% CH3CN gradient containing 0.1% TFA over 15 min., flow = 2 mL/min.
Kyushu Institute of Technology
45. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
46. Synthesis of trichostatin A like non-peptides
Scheme 4. Reagents and conditions: (a) AcSK, DMF, r.t.; (b) MeNH2/MeOH, R-Br, Et3N
Scheme 5. Reagents and conditions: (a) MeNH2/MeOH, DMF, Bzl-Br
Kyushu Institute of Technology
47. Enzyme inhibition and biological activity
*column: Chromolith performance RP-18e (100 x 4.6 mm)
eluent: 10-100% CH3CN gradient containing 0.1% TFA over 15 min.
Kyushu Institute of Technology
48. Scheme 6. Reagents and conditions: (a) Br(CH2)5Br/Br(CH2)4Cl, NaOEt, EtOH.; (b) AcSK, DMF, r.t.;
(c) MeNH2/MeOH, bromomethyl pyridine.HBr, Et3N
Scheme 7. Reagents and conditions: (a) Br(CH2)5COOEt/Br(CH2)6COOEt, NaOEt, EtOH.; (b) HCl.NH2-OH
KOH in MeOH
Kyushu Institute of Technology
49. Enzyme inhibition and biological activity
*column: Chromolith performance RP-18e (100 x 4.6 mm)
eluent: 10-100% CH3CN gradient containing 0.1% TFA over 15 min.
Kyushu Institute of Technology
50. Summary
• We have synthesized a library of non peptides inhibitors containing aromatic cap
groups similar to SAHA and TSA.
• We replaced the hydroxamic acid group of SAHA and TSA by several thioethers.
• The cell-free and cell-based HDAC inhibitory activity of inhibitors was evaluated
and it was found that most of the inhibitors shown activity in micromolar range
• Among SAHA analogues, the S-S hybrid shown better activity in presence of
DTT.
• Presence of methyl amide in cap group region of TSA like compounds didn't
show any abrupt change in activity.
• These non-peptide thioethers showed less activity as compared to cyclic
tetrapeptide thioethers, due to smaller aromatic cap groups.
Kyushu Institute of Technology
51. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
52. Amino suberoyl hydroxamic acid type HDAC inhibitors
1. Fairlie, D. P., et al. J. Med. Chem. 2006, 49, 7611-7622.
2. Miller, T., et al. Bioorg. Med. Chem. Lett. 2007 (in press).
3. Etzkorn, F. A., et al. J. Med. Chem. 2007, 50, 2003 -2006.
Kyushu Institute of Technology
53. Design of diketopiperazine hydroxamic acids
• Diketopiperazines are smallest cyclic dipeptide scaffolds found in many bioactive
molecules.
• The 2-amino-8-hydroxamido octanoic acid was incorporated into cyclic dipeptide
framework.
• Arrangement of aromatic ring on cyclic dipeptide framework, to know the binding
affinity of DKP cap group with surface of HDAC enzyme.
Kyushu Institute of Technology
54. • The diketopiperazine cyclic framework may act as cap group and
• Hydroxamic acid group will chelate with the Zn+2 ion of HDAC enzyme
H
N O His
H Zn+2
O N O
Asp
R N O Asp
H
Surface of Enzyme Active site pocket
Kyushu Institute of Technology
55. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
56. Design diketopiperazine hydroxamic acid containing
iminoacids
Design of cyclic dipeptides
cyclo(-L-Asu(NHOH)-L-Pro-)
cyclo(-L-Asu(NHOH)-D-Pro-)
cyclo(-L-Asu(NHOH)-L-Tic)
cyclo(-L-Asu(NHOH)-D-Tic-)
cyclo(-L-Asu(NHOH)-L-MePhg-)
cyclo(-L-Asu(NHOH)-D-MePhg-)
cyclo(-L-Asu(NHOH)-BzlGly-)
HN OH HN OH HN OH HN OH
R=
O O O O
Pro Tic MePhe BzlGly
Kyushu Institute of Technology
57. Synthesis of diketopiperazine hydroxamic acids
R = -CH3, -Bzl
AA = DL-Pro, DL-Tic, DL-MePhe and
BzlGly
O O
R1 R1
NH O NH O b
a
HN HN
O OH
O O
O O
R1 c R1
NH O NH O
HN O HN OH
N N
H H
O O
R1 = DL-Pro, DL-Tic, DL-MePhe and BzlGly
Scheme 1: Reagents and conditions (a) Pd-C, MeOH, H2. (b) HCl.H2N-OBzl, DCC, HOBt.H2O, Et3N
(c) Pd-BaSO4, AcOH, H2
Kyushu Institute of Technology
58. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
59. Design diketopiperazine hydroxamic acid containing
α ,α-dialkylated amino acids
Design of cyclic dipeptides
cyclo(-L-Asu(NHOH)-DL-A1in-)
cyclo(-L-Asu(NHOH)-A2in-)
cyclo(-L-Asu(NHOH)-DL-2MePhe)
cyclo(-L-Asu(NHOH)-L-2MePhg-)
cyclo(-L-Asu(NHOH)-D-2MePhg-)
R= NH N N
H
NH
O H O O
O
A1in A2in 2MePhe 2MePhg
Kyushu Institute of Technology
60. Synthesis of diketopiperazine hydroxamic acids
R = -CH3, -C2H5, -Bzl,
AA = DL-A1in, A2in, DL-2MePhe and
DL-2MePhg
O O
R1 a R1
NH O NH O
HN HN OH
O N
H
O O
R1 = DL-A1in, A2in, DL-2MePhe and DL-2MePhg
Scheme : Reagents and conditions (a) HCl.H2N-OH, NaOMe/MeOH, r.t.
Kyushu Institute of Technology
61. Enzyme inhibition and biological activity
*column: Chromolith performance RP-18e (100 x 4.6 mm)
eluent: 10-100% CH3CN gradient containing 0.1% TFA over 15 min.
Kyushu Institute of Technology
62. Summary
• We have synthesized a library of diketopiperazine hydroxamic acids by
introducing 2-amino-8-hydraxamido octanoic acid into cyclic dipeptide
framework..
• We did the arrangement of aromatic rings on cyclic dipeptide framework by
incorporating several imino acids and α,α-dialkylated amino acids.
• The cell-free and cell-based HDAC inhibitory activity of inhibitors was evaluated
and it was found that most of the inhibitors shown activity in micromolar range
• Compound 5 containing D-Tic showed good activity among synthesized
compounds
• Though hydroxamic acid is potent zinc ligand, but interaction of cap group with
surface of enzyme was not up to satisfactory level.
Kyushu Institute of Technology
63. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
64. Conclusions
• We have successfully synthesized a library of novel histone deacetylase inhibitors by arrangement
of aromatic ring on different cap groups like cyclic tetrapeptides, non-peptides and
diketopiperazines.
• The cell-free and cell-based HDAC inhibitory activity of the inhibitors was evaluated and it was
found that some of the compounds showed exciting results and some were disappointing.
• By the aromatic ring shifting in chlamydocin framework conformational changes were observed in
diastereomers. It further revealed an importance of aromatic ring position at cap group region ,
needed for better interaction with surface of HDAC paralogs.
• Lesser activity of non-peptides thioethers (with cap groups similar to SAHA and TSA) as compared
to cyclic tetrapeptide thioethers supports the fact that, macrocyclic cap group with proper
orientation of aromatic ring on its cyclic framework is necessary for better inhibition of HDACs.
• Primitive studies on diketopiperazine hydroxamic acids didn’t show expected activity, may due to
insufficient interaction of aromatic amino acids of diketopiperazine scaffold with the surface of
enzyme, which needs further investigation.
• To conclude, cyclic tetrapeptides with proper orientation of aromatic ring on their macrocyclic cap
group, are showing better interaction with surface of HDACs by inhibiting potently, as compared to
non-peptides and cyclic dipeptides.
• Therefore, cyclic tetrapeptide based HDAC inhibitors can be the challenging antitumor agents
Kyushu Institute of Technology
65. • Introduction
• Molecular design of histone deacetylase Inhibitors by aromatic ring
shifting
– Introduction
– Aromatic ring shifting in chlamydocin framework
– Variation of spacer length of L-Phe in chlamydocin
– Conformational changes due to aromatic ring shifting
• Molecular design of non-peptide inhibitors
– Introduction
– SAHA analogues
– TSA like non-peptides
• Molecular design of histone deacetylase Inhibitors by aromatic ring
arrangement on cyclic dipeptide hydroxamic acids
– Introduction
– Diketopiperazine hydroxamic acids containing iminoacids
– Diketopiperazine hydroxamic acids containing α, α,-dialkylated
amino acids
• Conclusions
• References
66. References
1. Grizinger, C. M., Schreiber, S. L. Chem. Biol. 2002, 9, 3-16.
2. Kouzarides, T. Curr. Opin. Genev. Dev. 1999, 9, 48.
3. Hassig, C. A., Schreiber, S. L. Curr. Opin. Chem. Biol. 1997, 1, 300-308.
4. Yoshida, M., Horinouchi, S., Beppu, T., Bioessays 1995, 17, 423-430.
5. Finnin, M. S., Donigian, J. R., Cohen, A., et al. Nature 1999, 401, 188-193.
6. Jose, B., Oniki, Y., Kato, T., Nishino, N., Sumida, Y., Yoshida, M. Bioorg. Med. Chem. Lett. 2004,
14, 5343-5346.
7. Furumai, R., Komatsu, Nishino, N., Khochbin, S., Yoshida, M., Horinouchi, S. Proc. Natl. Acad.
Sci. U.S.A. 2001, 98, 87-92.
8. Komatsu, Y., Tomizaki, K., Tsukamoto, M., Kato, T., Nishino, N., Sato, S., Yamori, T., Tsuruo, T.,
Furumai, R., Yoshida, M. Horinouchi, S., Hayashi, H. Cancer Res. 2001, 61, 4459.
9. Nishino, N., Jose, B., Okamura, S., Ebisusaki, S., Kato, T., Sumida, Y., Yoshida, M., Org. Lett,
2003, 5, 5079-5082.
10. Nishino, N., Jose, B., Shinta, R., Kato, T., Komatsu, Y., Yoshida, M. Bioorg. Med. Chem. Lett.
2004, 12, 5777-5784.
Kyushu Institute of Technology
67. Conference Presentations
1. Poster presentation: “ Design and synthesis of histone deacetylase inhibitors by aromatic ring shifting in
chlamydocin framework”. 29th European Peptide Symposium, Gdansk, Poland (2006).
Gururaj M.Shivashimpi, Satoshi Amagai, Tamaki Kato, Norikazu Nishino, Satoko Maeda,
Tomonori G. Nishino and Minoru Yoshida.
2. Poster Presentation: “Aromatic ring shifting in chlamydocin framework for specific inhibition of histone
deacetylase paralogs.” 43rd Japanese Peptide Symposium, Yokohama. Japan.(2006).
Gururaj M.Shivashimpi. Satoshi Amagai, Tamaki Kato, Norikazu Nishino, Junichi Nakagawa, Satoko
Maeda, Tomonori G. Nishino and Minoru Yoshida.
3. Poster presentation: “Toward potent HDAC inhibitor design: Insights from homology modeling and docking
simulation of HDAC and its inhibitors”. 5th East Asian Biophysics Symposium & 44th Annual Meeting of
the Biophysical Society of Japan, Okinawa, Japan (2006).
Hirashima Y., Shivashimpi G. M., Kato T., Nishino N., Maeda S., Nishino T. G., Yoshida M.
Kyushu Institute of Technology
68. List of publications
1. Design and synthesis of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.
Gururaj M. Shivashimpi, Satoshi Amagai, Tamaki Kato, Norikazu Nishino, Satoko Maeda, Tomonori G.
Nishino and Minoru Yoshida.
Proceedings of 29th European Peptide Symposium (J. Pep. Sci.) 2007 (in press)
2. Aromatic ring shifting in chlamydocin framework for specific inhibition of histone deacetylase paralogs.
Gururaj M. Shivashimpi. Satoshi Amagai, Tamaki Kato, Norikazu Nishino, Junichi Nakagawa, Satoko
Maeda, Tomonori G. Nishino and Minoru Yoshida.
Proceedings of 43rd Japanese Peptide (Peptide Science), 2006, 268-269.
3. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework
Gururaj M. Shivashimpi, Satoshi Amagai, Tamaki Kato, Norikazu Nishino, Satoko Maeda, Tomonori G.
Nishino and Minoru Yoshida.
Submitted to Bioorganic and Medicinal Chemistry.
4. Interaction of aliphatic cap group in inhibition of histone deacetylase inhibitors by cyclic tetrapeptides.
Norikazu Nishino, Gururaj M. Shivashimpi, Preeti B. Soni, Mohammed P. I. Bhuiyan, Tamaki Kato,
Satoko Maeda, Tomonori G. Nishino and Minoru Yoshida.
Submitted to Bioorganic and Medicinal Chemistry.
5. Effect of arrangement of aromatic ring on cyclic dipeptides containing 2-amino-8-hydroxamido octanoic
acid.
Gururaj M. Shivashimpi, Tamaki Kato, Norikazu Nishino, Satoko Maeda, Tomonori G. Nishino and
Minoru Yoshida. To be submitted to Bioorganic and Medicinal Chemistry.
Kyushu Institute of Technology
69. Acknowledgements
I am highly grateful to my supervisor Professor Norikazu Nishino (Kyushu Institute of Technology) for
giving me the rare opportunity to engage in this study and for arranging financial support throughout the
work.
My sincere gratitude to Prof. Tamaki Kato (Kyushu Institute of Technology) for his all time cooperation.
I express my thanks to Ms. Satoko Maeda and Prof. Minoru Yoshida (RIKEN) for measurements of
HDAC inhibitory activities
I would like to thank Dr. S. S. Pandey, Dr. Binoy Jose, Dr. M. P. I. Bhuiyan, and Dr. M. Muthukrishnan for
their support and encouragement throughout my research.
Many thanks to my Japanese friends Dr. L. Watanabe, Dr. Y. Hirashima, Mr. S. Okamura, Mr. S.
Ebisusaki and Mr. S. Amagai for their support and help in learning the peptide synthesis.
Many thanks to the present and past members of Nishino Laboratory for their kind support, encouragement
and making me to feel at home.
Finally, I am very much thankful to my father Mahadev C. Shivashimpi (Ret. High school Teacher), mother
Neelambika M. Shivashimpi, brother Veerendra, sisters Veeshalaxi and Shilpa, who were always
encouraging me during this work.